Related Experiment Video
Updated: Jul 12, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia
J F Kelleher1, P M Monteleone, D A Steele
1Department of Pediatrics, Baystate Medical Center, Springfield, Massachusetts, USA.
Journal of Pediatric Hematology/Oncology
|February 24, 2001
Summary
Children with leukemia and moderate liver dysfunction can tolerate aggressive chemotherapy. Current dose modification guidelines for liver disease may be too strict, suggesting potential benefits from adjusting them.
Area of Science:
- Pediatric Oncology
- Hepatology
- Hematology
Background:
- Hepatic dysfunction is a rare but serious complication in pediatric leukemia.
- Liver dysfunction can compromise chemotherapy efficacy and increase toxicity due to altered drug metabolism.
- Standard protocols often necessitate chemotherapy dose reductions for patients with liver disease.
Observation:
- This study reviewed literature and analyzed two pediatric leukemia cases with hepatic dysfunction.
- Previous research offers limited insight into managing leukemia with liver compromise.
- Institutional experience suggests moderate hepatic dysfunction may not preclude aggressive chemotherapy.
Findings:
- Children with leukemia and moderate hepatic dysfunction tolerated aggressive chemotherapy regimens.
- Aggressive chemotherapy administration was feasible despite impaired liver function in the observed cases.
Implications:
- Current pediatric leukemia treatment guidelines for dose modification due to liver disease may be overly conservative.
- Adjusting chemotherapy dosing protocols could allow for more effective treatment in children with leukemia and moderate hepatic dysfunction.
- Further research is warranted to refine chemotherapy dosing strategies for pediatric leukemia patients with hepatic compromise.
More Related Videos
Related Concept Videos
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...